Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia — STAR-VT  

Monomorphic Ventricular Tachycardia Clinical Trial

Official title: Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT) - G130132

Status Terminated

Clinical Trial Summary

To demonstrate that scar-based ventricular tachycardia (VT) ablation using the FlexAbility™ ablation catheter system results in a superior clinical outcome compared to routine drug therapy in subjects with documented Monomorphic Ventricular Tachycardia [MMVT] (both ischemic and non-ischemic) while maintaining an acceptable safety profile.

Clinical Trial Description

Approximately 50 centers in the United States (US) will participate in the study. Additional centers outside the US may be considered, as necessary. The anticipated enrollment duration is 48-60 months. ;

Related Conditions & MeSH terms

• Monomorphic Ventricular Tachycardia
• Tachycardia
• Tachycardia, Ventricular

• NCT number: NCT02130765
• Study type: Interventional
• Source: Abbott Medical Devices
• Status: Terminated
• Phase: N/A
• Start date: November 2014
• Completion date: July 25, 2016